Understand the source comparison
SS-LUP-332 Side Effects: Category Comparison
Gastrointestinal (nausea, diarrhea, cramping) 40–60% during titration 1–3 days post-initiation Dose escalation over 10–14 days; smaller meals Expected during adaptation phase; typically resolves by week 2–3 Thermogenesis (elevated core temp) 70–85% at moderate
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Gastrointestinal (nausea, diarrhea, cramping)
- 40–60% during titration
- 1–3 days post-initiation
- Dose escalation over 10–14 days; smaller meals
- Expected during adaptation phase; typically resolves by week 2–3
- Thermogenesis (elevated core temp)
- 70–85% at moderate to high doses
- 2–4 hours post-administration
- Hydration; avoid extreme heat environments
- Direct mechanism signal; dose-dependent and predictable
- Cardiovascular (tachycardia, BP changes)
- 40–55% at doses >5 mg/kg
- 2–6 hours post-dose
- Cardiovascular monitoring; reduce dose if HR >20% baseline increase
- Compensatory response to thermogenesis; concerning if persistent or severe
- Injection Site Reactions
- 25–40% per injection event
- Immediate to 24 hours
- Rotate sites; proper reconstitution technique; cold compress
- Chemical irritation, not immune reaction; preventable with protocol adherence
- Fatigue and Perceived Energy Deficit
- 30–50% during first 2 weeks
- Days 3–10 most pronounced
- Adequate sleep; avoid additional metabolic stressors
- Paradoxical but mechanistically consistent; improves with adaptation
- Sleep Disruption
- 30–40% when dosed evening
- First 7–14 days
- Morning administration; temperature management at night
- Timing-dependent; preventable with dose schedule adjustment